Masimo Corporation MASI recently received the CE mark and commercially launched the single-patient-use adhesive rainbow SuperSensor in Europe. The SuperSensor is compatible for use with both Masimo and third-party monitors with Masimo rainbow technology inside.
The all-inclusive, multi-purpose and handy SuperSensor utilizes 12 LEDs to simultaneously provide 12 blood constituent parameters noninvasively and continuously — all on the same single-patient-use adhesive sensor, which is an industry first.
The announcement is likely to provide a boost to Masimo’s patient monitoring platform and strengthen its product portfolio.
More on the News
It is worth mentioning that at the core of the SuperSensor lies Masimo Signal Extraction Technology (SET) pulse oximetry that has been clinically proven to aid care teams in improving patient safety and boosting patient outcomes.
Image Source: Zacks Investment Research
In this regard, this breakthrough technology enables clinicians to noninvasively and continuously monitor different physiologic indicators concurrently. This helps in tracking and assessing the patient’s status consistently.
Per management, the SuperSensor marks a critical milestone in Masimo’s sustained innovation, while mitigating concerns related to cross-contamination as it is a single-patient-use, adhesive product. The medical community is likely to benefit on the back of this innovative product.
Market Prospects
Per a report by Market Research Future, the global non-invasive monitoring device market is anticipated to witness a CAGR of 6.8% and is estimated to reach $21.59 billion by 2023. Rising adoption of non-invasive technology, and increasing prevalence of cardiovascular and neurovascular diseases are driving this market’s growth. Hence, this launch is a well-timed one for Masimo.
Recent Developments
This month, the company announced its collaboration with Penington Institute, which highlights its commitment toward increasing awareness regarding the risks associated with overdose from prescription opioids in spite of the directed usage.
In August, the company received the CE mark for its SafetyNet Alert and introduced the same in western Europe. Masimo SafetyNet Alert is an arterial blood oxygen saturation monitoring and alert system developed for utilization in a home setting. The system features SET wearable fingertip pulse oximetry sensor that offers wireless communication to an accompanying Home Medical Hub and smartphone app.
Again, in August, Masimo announced the findings of a study, published in the Turkish Journal of Emergency Medicine, wherein researchers explored the utility of noninvasive, continuous Masimo Pleth Variability Index (PVi) when it comes to monitoring volume status and changes in spontaneously breathing patients who are undergoing hemodialysis (HD). Per the findings, a strong correlation has been found between change in PVi and the volume of fluid removed.
Price Performance
Shares of the company have gained 20.7% in the past year compared with the industry’s growth of 14.8%.
Zacks Rank & Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. HSIC, Envista Holdings Corporation NVST and Merit Medical Systems, Inc. MMSI, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Henry Schein’s long-term earnings growth rate is estimated at 13.9%.
Envista Holdings’ long-term earnings growth rate is estimated at 27.4%.
Merit Medical’s long-term earnings growth rate is projected at 13.6%.
Tech IPOs With Massive Profit Potential
In the past few years, many popular platforms and like Uber and Airbnb finally made their way to the public markets. But the biggest paydays came from lesser-known names.
For example, electric carmaker X Peng shot up +299.4% in just 2 months. Think of it this way…
If you had put $5,000 into XPEV at its IPO in September 2020, you could have cashed out with $19,970 in November.
With record amounts of cash flooding into IPOs and a record-setting stock market, this year’s lineup could be even more lucrative.
See Zacks Hottest Tech IPOs Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report
Envista Holdings Corporation (NVST): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
